Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.38 USD
Change Today -0.32 / -3.68%
Volume 14.6K
IRIX On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GM
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

iridex corp (IRIX) Key Developments

Icare Finland plc and Iridex Corporation Enter into Distribution Cooperation

Icare Finland Plc signed a distribution agreement with Iridex Corporation related to Icare's TA01i instrument. Iridex plans to package the Icare TA01i with the Iridex Total Glaucoma Solution which includes the newly launched Cyclo G6 laser and the proprietary MicroPulse P3 device dedicated specifically to treat patients diagnosed with a range of glaucoma disease states. The Icare TA01i aids the physician in the diagnosis of glaucoma as well as post-operative assessment and monitoring of the patient's intra-ocular pressure. Iridex sold its first new Cyclo G6 glaucoma laser along with MicroPulse P3 disposable devices during the first quarter of 2015. The MicroPulse P3 device offers a repeatable, minimally invasive approach to slowing the progress of the disease and pushing off the need for more invasive surgical intervention. The Icare TA01i tonometer revolutionizes effective, early glaucoma detection by making the intra-ocular pressure measuring routine quick and easy for the patient as well as the physician.

IRIDEX Corporation Announces Consolidated Unaudited Earnings Results for First Quarter Ended April 4, 2015; Provides Earnings Guidance for the Second Quarter and Revenue Guidance for the Full Year of 2015

IRIDEX Corporation announced consolidated unaudited earnings results for first quarter ended April 4, 2015. For the quarter, the company reported total revenues of $10,796,000, income from operations of $403,000, income from operations before provision for income taxes of $396,000, net income of $246,000 or $0.02 basic and diluted per share compared to the total revenues of $10,329,000, income from operations of $597,000, income from operations before provision for income taxes of $500,000, net income of $487,000 or $0.05 basic and diluted per share for the same quarter a year ago. The effective tax rate of 37.9% against effective tax rate was only 2.6% for the same period a year ago. The company expects to achieve revenue of $48 million to $51 million for the full year 2015, although the company will continue to assess the impact to its business of the recent strong currency adjustments on a global basis. For the 2015 second quarter, the company anticipates revenue of $10.7 million to $11.1 million, gross margin is anticipated to come in between 49% and 51%, and operating expenses are expected to be $5.0 million to $5.2 million.

IRIDEX Corporation to Report Q1, 2015 Results on May 07, 2015

IRIDEX Corporation announced that they will report Q1, 2015 results at 5:00 PM, US Eastern Standard Time on May 07, 2015

IRIDEX Corporation, Q1 2015 Earnings Call, May 07, 2015

IRIDEX Corporation, Q1 2015 Earnings Call, May 07, 2015

IRIDEX Corporation Presents at UBS Global Healthcare Conference, May-19-2015 09:00 AM

IRIDEX Corporation Presents at UBS Global Healthcare Conference, May-19-2015 09:00 AM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: James H. Mackaness, Chief Financial Officer, Chief Operating Officer and Principal Accounting Officer, William M. Moore, Chairman of the Board, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IRIX:US $8.38 USD -0.32

IRIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bovie Medical Corp $2.89 USD 0.00
Ellex Medical Lasers Ltd A$0.35 AUD +0.02
MGC Diagnostics Corp $6.04 USD -0.03
Misonix Inc $10.90 USD -0.47
Utah Medical Products Inc $54.73 USD +1.02
View Industry Companies
 

Industry Analysis

IRIX

Industry Average

Valuation IRIX Industry Range
Price/Earnings 9.1x
Price/Sales 2.0x
Price/Book 2.5x
Price/Cash Flow 8.9x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IRIDEX CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.